We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test uncovers actionable disease-defining transcriptional biology. 

Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma. 

By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.

Health Data

Life Sciences

Medical Devices

Therapeutics

Precede Biosciences

Rehan Verjee

Matthew Eaton

Juliann Chmielecki

Corrie Painter

Kush Parmar

Jennifer Fortune

Geoff Otto

The Development Operations Team at Precede Biosciences is responsible for the optimization and integration of laboratory processes and workflows to support the company's genome-wide platform for profiling circulating chromatin and DNA methylome. This team ensures the technical accuracy and efficiency of assays, collaborates with scientific and clinical teams, and contributes to the development and validation of novel diagnostic tests, thereby facilitating precise, minimally invasive disease diagnosis and the advancement of new medicines.

Development Operations Team

Leadership Team

Product Development Team

Associate Directors

Development Operations Team

About

Team members

Other teams at Precede Biosciences

Leadership Team

Product Development Team

Associate Directors